Dated: February 12, 2001. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 01–4088 Filed 2–16–01; 8:45 am] BILLING CODE 4140-01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Mental Retardation Research Subcommittee, March 12, 2001, 8 a.m. to March 14, 2001, 5 p.m., Embassy Suites, Chevy Chase Pavilion, 4300 Military Rd., Wisconsin at Western Ave., Washington, DC 20015 which was published in the **Federal Register** on January 31, 2001, 66 FR 8418.

The meeting will be held on March 12–13, 2001. The meeting is closed to the public.

Dated: February 9, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy. [FR Doc. 01–4091 Filed 2–16–01; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Library of Medicine; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Biomedical Library Review Committee.

Date: March 7–8, 2001.

Closed: March 7, 2001, 8:30 a.m. to 11:30 a.m.

Agenda: To review and evaluate grant applications.

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Open: March 7, 2001, 11:30 a.m. to 2 p.m. Agenda: "Permanent Access to Electronic Information", Associate Director, Library

Operations, NLM.

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: March 7, 2001, 2 p.m. to 5 p.m. *Agenda:* To review and evaluate grant applications.

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: March 8, 2001, 8:30 a.m. to 10:30 a.m.

Agenda: To review and evaluate grant applications.

Place: National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Open: March 8, 2001, 10:30 a.m. to 11 a.m. *Agenda:* Remarks by the Director, NLM. *Place:* National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: March 8, 2001, 11 a.m. to 1 p.m. *Agenda:* To review and evaluate grant applications.

¹*Place:* National Library of Medicine, Board Room Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Contact Person: Milton Corn, MD, Associate Director, Office of Extramural Programs, National Library of Medicine, National Institutes of Health, One Rockledge Centre, Suite 301, 6705 Rockledge Drive, MSC 6075, Bethesda, MD 20892–6075, 301– 496–4621.

(Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: February 9, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy. [FR Doc. 01–4089 Filed 2–16–01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Method and Apparatus for Constructing Tissue Microarrays

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: None.

SUMMARY: This is notice, in accordance with 35 U.S.C 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the inventions embodied in: (1) U.S. Patent Application Serial No. 60/075,979 (PCT/ US99/04001) entitled "Tumor Tissue Microarrays for Rapid Molecular Profiling", provisionally filed February 24, 1998 and PCT filed February 24, 1999, and (2) U.S. Patent Application Serial No. 60/170,461 (PCT/US00/ 34043) entitled "Method and Apparatus for Constructing Tissue Microarrays", provisionally filed December 13, 1999 and PCT filed December 13, 2000, to Beecher Instruments Company having a place of business in Silver Spring, Maryland. The United States of America is an assignee to the patent rights of these inventions.

The contemplated exclusive license may be limited to the development of instruments for the construction of tissue microarrays for use for medical research and clinical diagnostics.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 23, 2001 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Uri Reichman, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 496–7056, ext. 240; Facsimile: (301) 402–0220; E-mail: reichmau@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent application.

SUPPLEMENTARY INFORMATION: The advent of the technology of Tissue Microarrays (also called "Tissue Chips") has made it possible to perform simultaneous molecular profiling of hundreds or even thousands of tissue samples in a high-throughput fashion. Tissue Microarrays include multiplicity of sub-millimeter tissue specimens, fixed and arranged on a single microscope slide. The technology provides means to generate hundreds of identical copies of the slides. These slides then can be used for specific molecular analyses, such as DNA and mRNA in situ hybridization and protein immunostaining. The subject

inventions, contemplated for the exclusive license, are directed towards the instruments used for the construction of tissue microarrays, and describe the design and the operations of these instruments. The method-of-use and the different applications of tissue microarrays for medical research and diagnostics are available for licensing by the NIH on a nonexclusive basis under a separate arrangement.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that established that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 12, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer. [FR Doc. 01–4093 Filed 2–16–01; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board to be held in March 2001. A portion of the meeting will be open and will include a Department of Health and Human Services drug testing program update, a Department of Transportation drug testing program update, and an update on the draft guidelines for alternative specimen testing and on-site testing.

If anyone needs special accommodations for persons with disabilities, please notify the Contact listed below.

The meeting will also include the review, discussion, and evaluation of sensitive National Laboratory Certification Program (NLCP) internal operating procedures and program development issues. Therefore, a portion of the meeting will be closed to the public as determined by the SAMHSA Administrator in accordance with Title 5 U.S.C. 552b(c)(2), (4), and (6) and 5 U.S.C. App.2, § 10(d).

A roster of the board members may be obtained from: Mrs. Giselle Hersh, Division of Workplace Programs, 5600 Fishers Lane, Rockwall II, Suite 815, Rockville, MD 20857, Telephone: (301) 443–6014. The transcript for the open session will be available on the following website: www.health.org/ workplace. Additional information for this meeting may be obtained by contacting the individual listed below.

Committee Name: Center for Substance Abuse Prevention Drug Testing Advisory Board.

Meeting Date: March 6, 2001; 8:30 a.m.– 4:30 p.m.; March 7, 2001; 8:30 a.m.–3:30 p.m.

Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, Maryland 20814.

Type: Open: March 6, 2001; 8:30 a.m.– Noon; Closed: March 6, 2001; Noon–4:30 p.m.; Closed: March 7, 2001; 8:30 a.m.–3:30 p.m.

Contact: Donna M. Bush, Ph.D., Executive Secretary, Telephone: (301) 443–6014, and FAX: (301) 443–3031.

Dated: February 13, 2001.

Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 01–4107 Filed 2–16–01; 8:45 am] BILLING CODE 4162–20–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY-920-09-1320-01, WYW152448]

Coal Lease Exploration License, WY

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of invitation for coal exploration license.

SUMMARY: Pursuant to section 2(b) of the Mineral Leasing Act of 1920, as amended by section 4 of the Federal Coal Leasing Amendments Act of 1976, 90 Stat. 1083, 30 U.S.A. 201 (b), and to the regulations adopted as 43 CFR 3410, all interested parties are hereby invited to participate with Bridger Coal Company on a pro rata cost sharing basis in its program for the exploration of coal deposits owned by the United States of America in the followingdescribed lands in Sweetwater County, WY:

T. 21 N., R. 99 W., 6th P.M., Wyoming

- Sec. 6: Lots 8–14, S2NE, SENW, E2SW, SE; T. 21 N., R. 100 W., 6th P.M., Wyoming
- Sec. 2: Lots 5–8, S2N2, S2; Sec. 4: Lots 5–8, S2N2, S2:
- Sec. 6: Lots 8–14, S2NE, SENW, E2SW, SE;
- Sec. 8: ALL;
- Sec. 10: ALL;
- Sec. 12: ALL;
- Sec. 14: ALL;
- T. 22 N., R. 100 W., 6th P.M., Wyoming
- Sec. 20: ALL;
- Sec. 22: ALL; Sec. 24: ALL;
- Sec. 24: ALL; Sec. 26: ALL:
- Sec. 28: ALL;
- Sec. 30: Lots 5–8, E2, E2W2;
- Sec. 32: ALL;
- Sec. 34: ALL.

Containing 10,250.500 acres, more or less.

All of the coal in the above-described land consists of unleased Federal coal within the Red Desert and Rock Springs Known Recoverable Coal Resource Areas. The purpose of the exploration program is to obtain information on the coal bearing seams and geologic formations in addition to obtaining the following characteristics: coal quality and quantity, Btu content, percent ash, percent moisture, percent sulfur and percent sodium data from the Fox Hills, Lance and/or Fort Union formations.

ADDRESSES: The proposed exploration program is fully described and will be conducted pursuant to an exploration plan to be approved by the BLM. Copies of the exploration plan are available for review during normal business hours in the following offices (serialized under number WYW152448): BLM, Wyoming State Office, 5353 Yellowstone Road, P.O. Box 1828, Cheyenne, WY 82003– 1828; and, BLM, Rock Springs Field Office, 280 Highway 191 North, Rock Springs, WY 82901.

SUPPLEMENTARY INFORMATION: This notice of invitation will be published in the "Rocket-Miner" of Rock Springs, WY, once each week for two consecutive weeks beginning the week of February 19, 2001, and in the Federal Register. Any party electing to participate in this exploration program must send written notice to both the BLM and Bridger Coal Company no later than thirty days after publication of this invitation in the Federal Register. The written notice should be sent to the following addresses: Bridger Coal Company, Attn: Scott M. Child, One Utah Center, Suite 2100, 201 South Main Street, Salt Lake City, UT 84140-0021 and the BLM, Wyoming State Office, Branch of Solid Minerals-922, Attn: Julie Weaver, P.O. Box 1828, Chevenne, WY 82003-1828.

The foregoing is published in the **Federal Register** pursuant to 43 CFR 3410.2–1(c)(1).